BioPharma APAC recently published its Top 26 - Companies Leading Sustainable Biopharma Practices in 2026, highlighting leading sustainability practices across pharmaceutical companies, biotechnology firms and CRDMOs in Europe, North America and Asia Pacific, with a focus on Science Based Targets initiative (SBTi) commitments, value-chain decarbonization, green manufacturing, and sustainable operations. The list brings together global pharmaceutical leaders – such as MSD (Merck & Co.), Eli Lilly, Johnson & Johnson, AstraZeneca, Takeda, GSK and Bayer – collectively illustrating the diverse pathways through which players across the industry value chain are advancing the green transition, with WuXi Biologics was featured for its outstanding sustainability practices, reflecting international industry recognition of the Company's empowering contributions through green CRDMO.
In Green Research, WuXi Biologics starts with "For Patients. For Planet." The Company leverages its integrated end-to-end CRDMO platform and innovative technologies to shorten the journey from molecule to patient. Discovery platforms such as WuXiBody™ accelerate the development of antibodies and complex molecules, improve developability and stability, and enable innovative therapies to reach patients faster, at greater scale and with higher quality. By simplifying bispecific antibody development and shortening R&D timelines by 6–18 months, WuXiBody improves R&D efficiency while reducing the natural resources and energy required to maintain research environments.
In Green Development, WuXi Biologics uses advanced platforms including WuXia, WuXiUP and WuXiUI to improve productivity, reduce resource use and provide more efficient and flexible process pathways for innovative biologics. The WuXia TrueSite cell line development platform further improves development efficiency and quality through technological innovation, achieving monoclonal antibody titers of 8–12 g/L — supporting high-yield commercial manufacturing requirements — and shortening to approximately six-month timeline from DNA to IND filing readiness. The WuXiUI ultra-intensified fed-batch platform boosts productivity by 3 to 8 times and reduces lifecycle environmental impacts by up to 60% compared with traditional fed-batch processes, making development lower-carbon, more efficient and more sustainable, while improving capacity, quality consistency and operational agility.